|
Business
Highlights
Rapid
Sales/Revenue Uptake:
The company operates a named patient supply programme
across Europe, planning to become to a
cash generative, self-funded company in the near term
Market
Exclusivity in US & EU for 10 years+:
Orphan
drug designation, granted & pending patents take IP
cover to 2025
Lower
Investment Risk:
Specialist drugs of this nature are a lower investment
risk, are more cost effective and fast tracked to market
High
Profit / Low Cost Business:
Low infrastructure, capital efficient business model;
providing high value specialist products in response to
unmet patient needs
Product
Pipeline Growth Strategy:
Negotiations with several
companies for further in-licensing, acquisitions and
revenue generating opportunities |
World-Class Team
Atlantic Healthcare
is led by a very experienced industry team (ex Elan, Eli
Lilly, Glaxo, Novartis, Pfizer, Wyeth), with a track
record of product acquisitions, launches and management,
together with successful private and public listed
company-building
Click to view the Atlantic Team.
Inflammatory Bowel Disease
Approximately 2m people suffer from Inflammatory Bowel
Disease (IBD).
The
pharmaceutical market for IBD is currently valued at
approximately $2bn and growing at approximately 10-15%
per annum, driven by unsatisfactory existing treatments
and the need for and use of new therapies
Atlantic
Healthcare is targeting the treatment of
pouchitis and ulcerative colitis which remain poorly
served diseases for which there is a need for more effective and safer
treatments |
